Acknowledgments
We would like to thank Professor Gini Ehungu Jean-Lambert and Doctor Domo Nina from the University Clinics of Kinshasa, Doctors Numbi Marcel and Iye Sandra from the University Clinics of Lubumbashi for their contribution in carrying out this work.

REFERENCES

  1. Ortiz MV, Dunkel IJ. Retinoblastoma. J Child Neurol 2016;31(2):227–236.
  2. Abramson DH. Retinoblastoma: Saving life with vision. Annu Rev Med 2014;65(1):171–184.
  3. Singh G, Daniels AB. Disparities in Retinoblastoma presentation, treatment, and outcomes in developed and less-developed countries. Semin Ophthalmol 2016;31(4):310–316.
  4. Weaver MS, Heminger CL, Lam CG. Integrating stages of change models to cast new vision on interventions to improve global retinoblastoma and childhood cancer outcomes. BMC Public Health 2014;14(1):1–12.
  5. Friedrich P, Lam CG, Itriago E, et al. Magnitude of treatment abandonment in childhood cancer. PLoS One 2015;10(9) ):e0135230.
  6. Naseripour M. “Retinoblastoma survival disparity”: the expanding horizon in developing countries. Saudi J Ophthalmol 2012;26(2):157–161.
  7. Olteanu C, Dimaras H. Enucleation refusal for retinoblastoma: a global study. Ophthalmic Genet 2016;37(2):137–43.
  8. Abramson DH, Shields CL, Munier FL, Chantada GL. Treatment of retinoblastoma in 2015: agreement and disagreement. JAMA Ophthalmol 2015;133(11):1341–1347.
  9. Chawla B, Singh R. Recent advances and challenges in the management of retinoblastoma. Indian Journal of Ophthalmology 2017;65(2):133–139.
  10. Aerts I, Lumbroso-Le Rouic L, Gauthier-Villars M, Brisse H, Doz F. Retinoblastoma update. Arch Pediatr 2016;23(1):112–116.
  11. Rodriguez-Galindo C, Orbach DB, Vanderveen D. Retinoblastoma. Pediatr Clin North Am 2015;62(1):201–223.
  12. Traoré F, Sylla F, Togo B, et al. Treatment of retinoblastoma in Sub-Saharan Africa: experience of the paediatric oncology unit at Gabriel Toure Teaching Hospital and the Institute of African Tropical Ophthalmology, Bamako, Mali. Pediatr Blood Cancer 2018;65(8):e27101.
  13. Mansell R, Purssell E. Treatment abandonment in children with cancer in Sub-Saharan Africa: systematic literature review and meta-analysis. Journal of Advanced Nursing 2018;74:800–808.
  14. Howard SC, Zaidi A, Cao X, et al. The My Child Matters programme: effect of public–private partnerships on paediatric cancer care in low-income and middle-income countries. Lancet Oncol 2018;19(5):e252–66.
  15. French African Pediatric Oncology Group (GFAOP) Accessed: 2020-07-15 https://www.gfaop.org/recherche-clinique.php.
  16. Ye H, Du Y, Chen R, et al. The potential benefit of three vs. six cycles of carboplatin, etoposide, and vincristine in postenucleation high-risk patients with IRSS stage I retinoblastoma. Curr Eye Res 2016 ;41(11):1507–1512.
  17. Mallipatna AC, Sutherland JE, Gallie BL, Chan H, Héon E. Management and outcome of unilateral retinoblastoma. J AAPOS 2009 ;13(6):546–550.
  18. Subramaniam S, Rahmat J, Rahman NA, et al. Presentation of retinoblastoma patients in Malaysia. Asian Pac J Cancer Prev 2014;15(18):7863–7867.
  19. Ali AA, Elsheikh SM, Elhaj A, et al. Clinical presentation and outcome of retinoblastoma among children treated at the National Cancer Institute (NCI) in Gezira, Sudan: a single institution experience. Ophthalmic Genet 2011;32(2):122–125.
  20. Boubacar T, Fatou S, Fousseyni T, et al. A 30-month prospective study on the treatment of retinoblastoma in the Gabriel Toure Teaching Hospital, Bamako, Mali. Br J Ophthalmol 2010;94(4):467–469.
  21. Venturi C, Bracco S, Cerase A, et al. Superselective ophthalmic artery infusion of melphalan for intraocular retinoblastoma: Preliminary results from 140 treatments. Acta Ophthalmol 2013;91(4):335–342.
  22. Sambo LG, Kirigia JM, Orem JN. Health financing in the African Region: 2000-2009 data analysis. Int Arch Med 2013;6(1):10.
  23. Balique H. Public hospital in French-speaking Africa. Med Trop(Mars) 2004;64(6):545–551.
  24. Bekibele CO, Ayede AI, Asaolu OO, Brown BJ. Retinoblastoma: the challenges of management in Ibadan, Nigeria. J Pediatr Hematol Oncol 2009;31(8):552–555.
  25. Traore F, Togo B, Sylla F, et al. Retinoblastoma: inventory in Mali and program to develop early diagnosis, treatments and rehabilitation. Bull Cancer 2013;100(2):161–165.
  26. Domingo RED, Toledo MSW, Mante BVL. Psychosocial factors influencing parental decision to allow or refuse potentially lifesaving enucleation in children with retinoblastoma. Asia-Pacific J Oncol Nurs 2017;4(3):191-196.
  27. Bhargav A, Singh U, Trehan A, Zadeng Z, Bansal D. Female sex, bilateral disease, age below 3 years, and apprehension for enucleation contribute to treatment abandonment in retinoblastoma. J Pediatr Hematol Oncol 2017;39(5):e249–253.
  28. Kumar A, Moulik NR, Mishra RK, Kumar D. Causes, outcome and prevention of abandonment in retinoblastoma in India. Pediatr Blood Cancer 2013;60(5):771–775.
  29. Radhakrishnan V, Kashyap S, Pushker N, et al. Outcome, pathologic findings, and compliance in orbital retinoblastoma (International Retinoblastoma Staging System stage III) treated with neoadjuvant chemotherapy: a prospective study. Ophthalmology 2012;119(7):1470–1477.
  30. Al-Obaid JA, Al-Megbel Y. Factors influencing retinoblastoma patients/siblings compliance with clinic appointments. Saudi Med J 2006;27(10):1561–1566.
  31. Luna-Fineman S, Chantada G, Alejos A, et al. Delayed enucleation with neoadjuvant chemotherapy in advanced intraocular unilateral retinoblastoma: AHOPCA II, a prospective, multi-institutional protocol in Central America. J Clin Oncol 2019;37(31):2875–2882.
  32. Howard SC, Pedrosa M, Lins M, et al. Establishment of a pediatric oncology program and outcomes of childhood acute lymphoblastic leukemia in a resource-poor area. JAMA 2008;291(20):2471–2475.
  33. Su WW, Kao LY. Retinoblastoma in Taiwan: The effect of a government-sponsored national health insurance program on the treatment and survival of patients with retinoblastoma. J Pediatr Ophthalmol Strabismus 2006;43(6):358–362.
  34. Cassoux N, Lumbroso L, Levy-Gabriel C, Aerts I, Doz F, Desjardins L. Retinoblastoma: update on current management. Asia-Pacific J Ophthalmol (Phila) 2017;6(3):290–295.
  35. Tomar AS, Finger PT, Gallie B, et al. A multicenter, international collaborative study for American Joint Committee on Cancer Staging of Retinoblastoma: Part I: metastasis-associated mortality. Ophthalmology 2020;127(12):1719-1732.
  36. Joko-Fru WY, Parkin DM, Borok M, et al. Survival from childhood cancers in Eastern Africa: a population-based registry study. Int J Cancer 2018;143(10):2409–2415.
  37. Global Retinoblastoma Study Group, Fabian ID, Abdallah E, et al. Global retinoblastoma presentation and analysis by national income level. JAMA Oncol 2020;6(5):685-695.
  38. Andreoli MT, Chau FY, Shapiro MJ, Leiderman YI. Epidemiological trends in 1452 cases of retinoblastoma from the Surveillance, Epidemiology, and End Results (SEER) registry. Can J Ophthalmol 2017;52(6):592–598.
  39. Rajeshuni N, Whittemore AS, Ludwig CA, Mruthyunjaya P, Moshfeghi DM. Racial, ethnic, and socioeconomic disparities in retinoblastoma enucleation: a population-based study, SEER 18 2000-2014. Am J Ophthalmol 2019;207:215–223.
  40. World Health Organization. Global initiative for childhood cancer 2020. Available from: https://www.who.int/publications/m/item/global-initiative-for-childhood-cancer. Accessed:2022-03-04